secwatch.observer — SEC 8-K summary
======================================

Issuer:     SKINVISIBLE, INC. (SKVI)
CIK:        0001085277
Form:       8-K
Filed at:   2024-10-03T23:59:59+00:00
Accession:  0001663577-24-000257
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skinvisible announces 99.6% transdermal penetration of GLP-1 drug in preclinical study
--------------------------------------------------------------------------------

- GLP-1 drug danuglipron formulated with Invisicare showed 99.6% penetration over 6 hours in Franz cell diffusion studies.
- CB-1 antagonist formulated with Invisicare showed 62% penetration over 6 hours; sustained delivery with no initial spike.
- Company is developing other GLP-1 agonists and CB-1 antagonists for transdermal obesity treatment.
- Seeking strategic partnerships to bring first transdermal obesity therapies to market.
- Obesity drug market projected to reach $105B-$144B by 2030 per Morgan Stanley.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1085277/000166357724000257/0001663577-24-000257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1085277/000166357724000257/skvi8k_100324.htm
  HTML page:      https://secwatch.observer/filing/0001663577-24-000257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer